N-acetylcysteine (NAC) is administered to prevent and/or treat hepatotoxicity associated with acetaminophen overdoses. Ideally, intravenous NAC is initiated early (i.e. within 8-10 h). Intravenous NAC is administered as a loading dose followed by two maintenance doses, each with different infusion rates. The total dose of NAC is 300 mg/kg administered over 20.25-21 h (15 vs. 60 min load). Dose is adjusted for obese patients and total volume administered is adjusted for patients under 40 kg. Given the complexity of the dosing regimen, medication administration errors occur frequently, in as many as a third of patients. Studies of intravenous NAC's effectiveness in early presenting acute acetaminophen overdoses have reported hepatotoxicity in up to 10% of cases. These findings indicate that the 21-h regimen is suboptimal in some patients. Factors associated with poor outcomes in early presenters may include high initial plasma acetaminophen concentrations, persistently elevated plasma acetaminophen concentrations and product formulation. To assure optimal outcomes an individualized approach to discontinuing therapy is needed. This presentation will discuss strategies to mitigate medication administration errors as well as identify patients who require longer courses of intravenous NAC therapy. Medication errors are a common cause for iatrogenic adverse drug events. The incidence and nature of medication errors during pre-hospital treatments has not been fully described. The objectives of this paper are to describe the incidence and characteristics of medication errors in adults during pre-hospital emergency treatments, and during the treatment in the emergency department (ED) and to identify risk factors for medication errors in these settings. A retrospective study of adult patients transferred to the ED of a university affiliated hospital in Israel by emergency medical services, from January 1st to December 31st 2007. Drugs administered in the mobile intensive care unit (ICU) and in the ED were reviewed by two reviewers who independently decided whether or not an error occurred. The primary outcome was the number of drug errors per patient. One thousand eight hundred and thirty seven patients were brought to the ED by mobile ICU's. Five hundred thirty-six (29%) patients' charts were randomly selected for review. Sixty-five (12.12%) charts could not be found, thus 471 remaining charts were included in our study. One hundred and eighty-eight patients (45.63%) received medications in the mobile ICU, of these, 24 patients (12.76%) were subjected to a medication error. In the mobile ICU, the number of drugs administered and long evacuation time were associated with higher risk for an error [(P<0.01) and (P=0.011), respectively]. No association was found between the presence of a medical doctor in the emergency vehicle and the risk of an errors (CI=0. 998-11.350). Three hundred thirty-two patients receive medications in the ED (72.6%). Medication error was found in 120 patients (36.1%). A higher risk for error was found in patients treated with large number of medications (P<0.01).
N-acetylcysteine (NAC) is administered to prevent and/or treat hepatotoxicity associated with acetaminophen overdoses. Ideally, intravenous NAC is initiated early (i.e. within 8-10 h). Intravenous NAC is administered as a loading dose followed by two maintenance doses, each with different infusion rates. The total dose of NAC is 300 mg/kg administered over 20.25-21 h (15 vs. 60 min load). Dose is adjusted for obese patients and total volume administered is adjusted for patients under 40 kg. Given the complexity of the dosing regimen, medication administration errors occur frequently, in as many as a third of patients. Studies of intravenous NAC's effectiveness in early presenting acute acetaminophen overdoses have reported hepatotoxicity in up to 10% of cases. These findings indicate that the 21-h regimen is suboptimal in some patients. Factors associated with poor outcomes in early presenters may include high initial plasma acetaminophen concentrations, persistently elevated plasma acetaminophen concentrations and product formulation. To assure optimal outcomes an individualized approach to discontinuing therapy is needed. This presentation will discuss strategies to mitigate medication administration errors as well as identify patients who require longer courses of intravenous NAC therapy. Medication errors are a common cause for iatrogenic adverse drug events. The incidence and nature of medication errors during pre-hospital treatments has not been fully described. The objectives of this paper are to describe the incidence and characteristics of medication errors in adults during pre-hospital emergency treatments, and during the treatment in the emergency department (ED) and to identify risk factors for medication errors in these settings. A retrospective study of adult patients transferred to the ED of a university affiliated hospital in Israel by emergency medical services, from January 1st to December 31st 2007. Drugs administered in the mobile intensive care unit (ICU) and in the ED were reviewed by two reviewers who independently decided whether or not an error occurred. The primary outcome was the number of drug errors per patient. One thousand eight hundred and thirty seven patients were brought to the ED by mobile ICU's. Five hundred thirty-six (29%) patients' charts were randomly selected for review. Sixty-five (12.12%) charts could not be found, thus 471 remaining charts were included in our study. One hundred and eighty-eight patients (45.63%) received medications in the mobile ICU, of these, 24 patients (12.76%) were subjected to a medication error. In the mobile ICU, the number of drugs administered and long evacuation time were associated with higher risk for an error [(P<0.01) and (P=0.011), respectively]. No association was found between the presence of a medical doctor in the emergency vehicle and the risk of an errors (CI=0.998-11.350). Three hundred thirty-two patients receive medications in the ED (72.6%). Medication error was found in 120 patients (36.1%). A higher risk for error was found in patients treated with large number of medications (P<0.01).
Prescribing Errors in Emergency Conditions
Less errors were found in trauma patients (P=0.041) (CI= 1.031-4.566). The risk of an error in the ED was higher than the risk for an error in the mobile ICU (p<0.001). Hepatic injury associated with paracetamol dosing has been a "hot button" issue in the United States. Of particular interest has been "inadvertent" overdose from therapeutic error-taking more than one preparation of paracetamol simultaneously. We sought to use post marketing surveillance data from US poison centers, along with US prescription data to explore the incidence of hepatic injury from non-suicidal exposure to combinations of opioid and paracetamol products-over time and with various patterns of exposure. The AAPCC NPDS database for 2000-2007 involving exposures to one or more opioids (hydrocodone, oxycodone, codeine, tramadol, methadone, morphine, fentanyl, hydromorphone) along with paracetamol (separately or in combination) was obtained. This dataset was limited to age≥13 years. Suicidal cases were excluded. Exposures were characterized as to none, one, or more than one combination product, and to paracetamol in combination only or additionally. Opioid prescription data were obtained Use of one paracetamol product was more likely to result in injury than use of more than one product (p=0.0004). The incidence of injury related to opioid/paracetamol use has increased dramatically. Although the rate of injury was lower, most injuries were from overuse of a single opioid/paracetamol product alone. Abuse and misuse accounted for most for the injuries. In contrast, paracetamol only exposure and injury rose more slowly. With paracetamol only, injury was almost exclusively the result of single product overuse, not simultaneous use of more than one paracetamol containing product.
Medication Errors in the Elderly
Michael A. McGuigan Long Island Regional Poison Center, Winthrop-University Hospital, Mineola, NY, USA
Medication errors in the elderly are a serious global health problem. A medication error can be considered to be anything that goes wrong in the process that begins with the physician prescribing and ends with the patient taking the medication as directed. The result of a medication error is referred to as an adverse drug event (ADE). The types of medication errors include inappropriate prescribing (using a drug with higher ADE risk instead of an effective lower risk drug), over-and under-use of medications, the use of drugs that provide no benefit, nonessential drugs (not indicated, ineffective, and duplications), and contraindicated drugs. Medication errors may occur in a health care facility or at home. This presentation will focus on the transition periods, home-to-hospital and hospital-to-home. Deliberate self-poisoning (DSP) is the most common method of attempted suicide. Long-term outcome of patients surviving DSP has not been adequately explored.
We conducted a population-based study in Ontario (∼12.6 million residents), Canada between 1991 and 2005. All admitted patients for a first DSP were identified. Demographics, medical, and psychiatric history were recorded. Subsequent episodes during the study period were identified from the same database. Death-of-all-cause was recorded, and rate was compared to age-and gendermatched controls from the same population. Of 29,739 patients admitted with a first episode of DSP, 3,799 (13%) were admitted for another DSP, and a third of the latter, had multiple admissions. Female to male ratio was 1.7 and 1.9 in single DSP and repeat DSP, respectively. Median time to re-admission for DSP was 423 days, with 54% and 10.6% of repeat suicide attempts occurring >1 and >5 years after the index attempt, respectively. Overall death rate was fourfold higher in the DSP group compared to gender-and age-matched controls. DSP survivors are at a high risk for early death, which carries significant societal implications. Admission for a recurrent DSP occurs at a high rate (one in eight), and the majority occurs more than a year after the index event, suggesting that short-term studies and interventions fail to detect a considerable proportion of events or identify high-risk populations. In general, adults do not learn well.
More and more studies demonstrate the need for interactive and engaging learning in medicine. This session will introduce new formats and technologies of educating at all levels of learners in the field of medical and clinical toxicology. Patient simulation systems create a virtual hospital environment using sophisticated software, video graphics, and life-size mannequins that allow learners to perform common medical procedures and respond to common, rare or complex medical overdose scenarios. SECT explores knowledge development and clinical decision making in computer based simulation activities. Simulation engages learners at multiple levels of their education thereby facilitating team building and active leadership roles for learners. The presentation will discuss the incorporation of practice-based learning and core competencies. The session will discuss how to incorporate the use of real medications and the development of an antidote cart. I will present the use of a DVD recording to provide real-time feedback and evaluation of the learner. I will also present guidelines and samples of case scenarios that can be used at the learner's home institution. The major advantages and limitations of patient simulation will be discussed. This presentation can be associated with an interactive session/workshop.
The Importance of Toxicologic Research in Global Health
Lewis R. Goldfrank Department of Emergency Medicine, NYU School of Medicine, New York City Poison Center, New York, NY, USA Global health advances are highly dependent on the stage of development of sustainable health resources in the individual country, an issue that is critically important in the developing world. The role of international toxicologic collaboration will be enhanced by strong public policy efforts with regard to protecting the environment, protecting food, water and drugs, and occupational safety efforts, while simultaneously developing an adequate quality and quantity of pharmacologists and toxicologists in developed and developing countries. The author discusses the morbidity and mortality associated with pesticides and herbicides in the developing world. The link between the economic instability of the farmer in the developing world, poverty, depression, limited access to mental health services, the ready availability of herbicides and pesticides, the extreme toxicity of these compounds, the uncertainty of the quality and efficacy of antidotes and the variable quality of essential health services (EMS, EDs, ICUs, PCCs) make the availability of pesticides and herbicides of immense intellectual, social, environmental, occupational, and public health importance. An organized approach to the prevention and management of intentional and unintentional pesticide and herbicide poisoning is discussed focusing on the essential human services appropriate to assure the public's health. Even with these international and national variations in the patterns of recreational drug use, their background population use is relatively low compared to that seen in individuals who frequent the night-time economy (i.e., bars, nightclubs, discotheques, and raves). The availability, and therefore patterns of use, of recreational drugs changes over time, driven not only by changes in legislation to control novel substances, but also changes in the sourcing and availability of different substances. In the latter part of the twentieth century, the commonest drugs used recreationally included cocaine, ketamine, and amphetamines including MDMA (ecstasy). Typically, these drugs were sourced from street-level drug dealers and they became controlled under relevant international and national legislation. The increase in the use of the Internet towards the end of the twentieth century and into the twenty-first century has changed not only the patterns of substances being used recreationally, but also the methods by which they are sourced. These novel psychoactive substances provide both healthcare and legislative authorities with an ongoing and developing challenge. Novel psychoactive substances that have appeared on the recreational drug scene over the last 5-10 years include the piperazines, the cathinones, and the substituted amphetamines; all of these have a similar structure and activity to other phenylethylamines such as amphetamine. Some of these compounds have not had a more generalized acceptance in the recreational drug scene, either due to unwanted effects or a lack of desired effects, whereas some have become more established "competitors" to more classical recreational drugs. This is particularly notable for the cathinones, largely as users report that they have the desired effects and are very comparable to more established drugs. The final group of drugs that have emerged over the last 5 years are the synthetic cannabinoid receptor agonists, commonly found in smoking mixtures referred to as "Spice" or K2.
Novel Recreational Drugs and "Legal
Presentations to healthcare facilities with acute toxicity associated with the use of novel psychoactive substances is typically similar to that seen with more classical stimulant or sympathomimetic recreational drugs such as amphetamine and cocaine. This presents a challenge to clinical toxicologists in determining the true pattern of toxicity associated with individual novel psychoactive substances. Firstly, the majority of individuals are polysubstances users and therefore are unlikely to present with toxicity associated with the use of a single substance. Secondly, individuals may not actually be aware of exactly what they have taken, as the substances that they have used may not contain what they believe that they do. Finally, not only is routine toxicological screening not undertaken in the majority of individuals with acute toxicity, but the interpretation of this is limited by the range of compounds listed in the analytical library. Although in some countries, such as the UK, some of these novel psychoactive substances may be controlled by existing generic legislation, and in other countries, such as the USA, they may be controlled under analogue legislation, the majority of these novel psychoactive substances when they first appear on the recreational drug scene will fall outside the relevant international and national legislation. This presents a challenge to politicians and legislative authorities as to how to not only adapt legislation to control a rapidly evolving recreational drug market, but also to ensure that this legislation and control is appropriate to the availability, use, and patterns of harm associated with the novel psychoactive substances. Clinical toxicologists play an essential role in the control and dissemination of information in regards to this everchanging recreational drug scene. They need to be alert to novel substances that are appearing in the market place, undertake targeted screening to determine the prevalence of use of these novel substances and finally use this information to describe the true pattern of acute toxicity associated with the use of novel psychoactive substances.
Clinical Consequences of Additives in Drugs of Abuse
Silas Smith NY University School of Medicine, NY University School of Medicine, Department of Emergency Medicine, Bellevue Hospital Center, New York, NY, USA
The purity of "street drugs" may become compromised by a variety of intentional and unintentional contaminants due to attempts to increase apparent product, marketing strategies, manufacturing pressures, or inattention to production techniques. Diluents, manufacturing byproducts, outright drug substitutions, and pharmacologically active adulterants with synergistic, antagonistic or alternative effects may produce unanticipated clinical effects and complicate toxidrome identification. Epidemic poisonings occur periodically due to these introduced xenobiotics. This talk will review the presentation and evolution of past epidemic drug poisonings in which heroin and opioids, cocaine, methcathinone, and methamphetamine were contaminated with quinine, strychnine, scopolamine, clenbuterol, botulinum spores, MPTP, manganese, lead, diphenhydramine, and fentanyl derivatives. These adulterants complicated clinical management and generated significant patient morbidity and mortality. Emerging contaminants including levamisole, xylazine, and Nbenzylpiperazine will also be explored.
Sophisticated Controlled Substance Act is Needed
Ehud Wolf Division of Identification and Forensic Science (DIFS-MAZAP), Israel Police, HQ, Jerusalem, Israel
The real designers of the "designed drugs" are the legal authorities. As long as legal highs distributors will avoid selling illegal drugs, the best and common goods at the 24/7 stores and the legal Internet sites will be fit and not included in the CSA. About a year is needed in order to add a substance to the CSA. Generic and specific CSAs need a lot of changes every year otherwise they will not be fitted to the substances seized at the streets as "legal drugs". Forensic identification should not be the starting point of the material into the CSA. The well-known process of identification of forensic exhibits is long and clumsy for these materials-most of them isomers and derivatives of illicit drugs. Investigation units and prosecutors cannot wait until the forensic labs will update their arsenal of standard materials and will make them ready for comparison. A lot of scientific work is needed until a new standard is synthesized, prepared from an exhibit or received from another unit and is ready to use. Authorities must internalize that "a new active substance is born and seized every day". They have to be prepared today, not tomorrow, and changing the CSA to a generic one is not a magic medicine. It is a long process and has its own problems. At the end of the process of adding a substance into the CSA, authorities have to know that people on the other side do not waste their time. They work hard to get rid of their old stock, and to develop a new generation of legal highs, sometimes more effective, well-designed, and hard to identify. These materials consider the limits of the new version of CSA just published, and now, they took a place on the 24/7 shelves. Sophisticated wording of the CSA, using different legal possibilities of control, and cooperation between states in enforcement and in CSA wording must play a crucial factor in the role of drug enforcement. Furthermore, it was checked whether these drugs and/or their metabolites can be detected in urine samples. Finally, human cytochrome-P450 isoenzymes were identified responsible for the main metabolic steps. Usually, rat urine samples were worked-up after administration of 20 or 1 mg/kg body mass for toxicological diagnostic reasons. Metabolites were separated and identified by GC-MS and/or by LC high resolution MS. For toxicological detection, the urine samples were analyzed after acid hydrolysis followed by liquid-liquid extraction, acetylation, and full-scan GC-MS. In order to investigate the involvement of particular CYP enzymes in the main metabolic steps, incubations were performed with the ten most important human CYP isoenzymes or human liver microsomes. Analysis of the urine samples revealed phase-I main metabolic steps for all drugs: for instance reduction of the beta-keto moiety to the corresponding alcohols (beta-keto drugs), oxidation of the pyrrolidine ring to the lactam (pyrrolidinophenones), or N-oxidation (fentanyl derivatives). Furthermore, phase-II metabolites were identified using the LC-HRMS approach. Using a well-established screening procedure, the drugs and/or their metabolites could be detected in rat and/or human urine. Finally, the isoenzymes forming the initial metabolites could be identified. Reference: Meyer MR, Maurer HH (2010) Curr Drug Metab 11:468-482.
Pitfalls of Roadside SFSTS and DRE Testing in Identifying Impaired Drivers
Joseph Citron Atlanta, GA, USA Roadside testing for alcohol and/or drug impaired drivers involves Standardized Field Sobriety Testing and 12 step Drug Recognition Examinations. There are a multitude of pitfalls encountered when these tests are used. The lack of specificity, lack of statistical reliability and the polypharmacy of our society are some of the problems encountered when using these tests. This presentation will review the SFST and DRE problems and add historical background. were beneficial in ameliorating the initial injury and in delaying corneal pathology in the late phase, if given during the first week. When the steroid was given as a symptomatic treatment against NV, a significant regression of the blood vessels was observed, however the effect was temporal and angiogenesis reappeared. Much is known about the health consequences of marine algal blooms, e.g., red tide caused by the algae Gymnodinium breve. However, growing concern is over the health of humans who might be exposed to the myriad of more sparsely studied algal toxins that bloom in freshwater bodies worldwide. Freshwater lakes and reservoirs provide recreation, livelihood and drinking water sources for millions of people. This presentation indicates the severity of toxins associated with freshwater algal blooms and attempts to extend the knowledge void of the more germane toxicological issues associated with these toxins. Specific toxins associated with cyanobacteria will be discussed, including lipopolysaccharide endotoxins, neurotoxins, and hepatotoxins, associated with the gramnegative cell walls and are found in all cyanobacteria. Some cyanobacteria produce low molecular weight alkaloids intracellularly, which are also neurotoxic and hepatotoxic and are comprised of anatoxins (ATXs). ATXs are of three types: anatoxin-a, homoanatoxin-a, and anatoxin-a(s) and are linked to the cyanobacterial genera Anabaena, Oscillatoria (Planktoothrix), Aphanizomenon, and Lyngbya. Anatoxin-a and homoanatoxin-a are structurally related cholinergic agonists. They are postsynaptic acetylcholine mimics, which cannot be broken down by acetylcholinesterase. The potential human health implications of these toxins indicate that their study in freshwater lakes is of high heuristic value. The physiological and biochemical mechanisms of these and various other toxins will be discussed.
Environmental Obesogenes-From Basic Science to Speculation: Are They Responsible for the "Obesity Epidemic"?
Avi Wiener
Institute of Occupational & Environmental Medicine, Rambam Health Care Campus, Haifa, Israel
Obesity is an epidemic in the industrialized Western countries. The conventional wisdom holds that it is primarily driven by a prolonged positive energy balance. Recent findings highlight the possible involvement of environmental chemicals that can disrupt the normal development and homeostasis controls over adipogenesis and energy balance. Grün and Blumberg defined them as "environmental obesogens". The process by which adipose cells are derived from a mesenchymal pre-adipocyte involves an orchestrated series of differentiation steps mediated by a cascade of specific transcription factors. Of particular importance is the activation of the nuclear receptor (NR) peroxime proliferator-activated receptor γ (PPARγ) that heterodimers with another NR, the retinoic X receptor (RXR) and binds to specific promoter region of target genes of the pre-adipocyte and regulates its expression. Organotins and other xeno-chemicals are potent nanomolar agonist ligands for the NRs RXR and PPARγ. In vitro and in vivo studies on animals showed that they could activate RXR-PPARγ-dependent pre-adipocytes gene network and regulate adipocytes number, size and function, i.e., causing obesity. Whether the action of obesogens in animals is largely well established, the connection to human epidemiology is less so, and many questions remain to be answered. Although there is abundant evidence that diet and exercise are keyfactors in the obesity epidemic, it is tempting to speculate that environmental obesogens might play a role in the obesity epidemic.
Determining Causation in Clinical Neurotoxicology: A Critical Appraisal
Carlos Fernando Collares Universidade Cidade de São Paulo (UNICID), Curso de Medicina, São Paulo, Brazil
It may be difficult for the physician to determine causation of clinical manifestations occurring after neurotoxic exposure. Contemporary medical education frequently ignores toxicology and environmental health. Systematic toxicosurveillance programs that should provide clinical evaluation of exposed populations as well as recognition and publication of previously unknown toxic effects are often inexistent or underdeveloped.
Interinstitutional and interdisciplinary research on Neurotoxicology is still insufficient to perform an appropriate number of multicentric observational studies and case reports. Ambient urban air pollution has been shown to cause airway hyper-secretion, constriction and obstruction. Recent literature reveals the impact of air pollution on cardiovascular physiology including arrhythmia and atherosclerosis. We will review the toxicological and epidemiological literature on the effects of ambient urban air pollution including fine particulates, gaseous ozone, NOx and SOx. Participants will also be able to describe the effect of air pollution trends on ER admission rates and daily mortality. As a case study we will discuss the Haifa Bay Area, known to have the worst air quality and highest rates of cancer and asthma in Israel. We will analyze the various sources of air pollution in the region, its impact on the health of the community and burden on the medical system.
Biological Markers of Fetal Toxicity
Gideon Koren Motherisk Program, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
It is critical to estimate fetal exposure to drugs of abuse, ethanol, and other toxic substances in the diagnosis and prognosis of these cases. The first attempt that the author has been able to identify of the treatment of a poisoning with ILE was in 1997 in a Czech language publication describing the successful treatment of poisoning by the lipophilic pesticide paraquat with a regimen that included the administration of ILE preparations designed for use with parenteral nutrition. 3 The potential therapeutic utility of a lipid-chemical interaction was first rigorously studied in 1998 by Guy Weinberg utilizing a rat model of bupivacaine-induced cardiac arrest. 4 In the Weinberg model, rats were resuscitated from cardiac arrest with either saline or 30% ILE. Intravenous lipid therapy was associated with an approximately 50% increase in the LD 50 for bupivacaine. Twenty-three additional fully published English-language animal studies have been identified by the author. These studies are comprised of seven on local anesthetics, five on beta-receptor antagonists, three on cyclic antidepressants, four on verapamil, and one each on thiopentone, moxidectin, paraoxon, and asphyxia. Twenty of the 24 controlled studies showed often very dramatic beneficial effects of ILE, including those with the end point of resuscitation from full cardiac arrest. In comparative studies ILE was superior to saline, vasopressin, epinephrine, and in the case of verapamil, to atropine and calcium. In contrast, in asphyxial cardiac arrest ILE was not superior to standard Advanced Cardiac Life Support. 5 Human experience with ILE is anecdotal. The author has identified 27 published English-language reports. These have documented successful resuscitations including sever-al cases of apparent dramatic reversal of prolonged cardiac arrest with a lack of subsequent neurological deficits. Twenty of the human case reports have involved local anesthetics. To date, there have been no major adverse effects of ILE reported. However, ILE appears to be less effective in animal models when high doses of epinephrine are administered. 6, 7 Based on a critical analysis of this literature, it may be concluded that there is clear and unambiguous evidence of the efficacy of ILE in animal models. In contrast, "real world" experience with poisoned humans is completely anecdotal and, undoubtedly, suffers from the publication bias inevitably associated with the very low likelihood that the non-resuscitated patient would be published. Power considerations suggest that it is unlikely that there will be a prospective controlled clinical trial of ILE in humans. However, prospective accumulation on experience with ILE has now been undertaken by several ongoing studies. Theories regarding the mechanism of intravenous fat emulsion for bupivacaine cardiotoxicity include (1) an improvement of impaired cardiac metabolism and (2) that lipid infusion creates an intravascular sink into which the cardiotoxic drug is sequestered. However, work in this area is inconclusive and a more mechanistic explanation is desirable. We used single cell isolation and voltage clamp techniques to study the electrophysiologic effects of bupivacaine, polyunsaturated, and saturated fatty acids on sodium current (iNa) in stable cell lines expressing human cardiac sodium channels. Linolenic (polyunsaturated) and stearic acid (saturated) were selected for study as they are significant components of commonly used lipid infusions. Bupivacaine induced significant tonic and use dependent iNa block, as expected. Fatty acids directly modulated iNa, and induced tonic but not use dependent block. Greater block was seen with polyunsaturated fatty acids compared to saturated fatty acids. Simultaneous exposure to bupivacaine and fatty acids reduced both the tonic and use dependent block compared to bupivacaine alone. Reduction of bupivacaine induced iNa block was greatest in cells treated with polyunsaturated fatty acids. Salutary effects of intravenous fat emulsion may be, in part, due to a direct effect on sodium channels and an ability to modulate bupivacaine iNa blockade.
QT Interval: A Prolonged Discussion

Lewis Nelson
New York University School of Medicine, New York, NY, USA
The QT interval on the electrocardiogram represents the period during which the ventricle is in systole and myocardium is undergoing relaxation and repolarization. Drug-induced prolongation of this interval is associated with polymorphic ventricular tachycardia (torsades de pointes) and may lead to syncope or sudden cardiac death. A prominent mechanism through which drugs and toxins prolong this interval is by blockade of myocardial potassium channels. Potassium ion efflux counterbalances calcium ion inflow and maintains the plateau phase of the cellular action potential. Slowing the rate of efflux of potassium prolongs repolarization, which manifests as QT prolongation. Although QT prolongation itself is of little consequence, the underlying pathophysiology of altered cellular repolarization produced raises the likelihood that an ectopic beat will occur (via early afterdepolarization). It simultaneously alters the myocardial tissue to make it favorable for this ectopic beat to capture and leads to a reentrant dysrhythmias, such as torsades de pointes. Many structurally unrelated drugs and toxins alter repolarization through effects on the potassium channel. This diversity of agents suggests that the potassium channel is "promiscuous." For this reason all new drugs marketing in the US are required to undergo testing for in vitro effects on potassium currents and by electrocardiographic changes in human subjects as appropriate.
Acetic Acid Poisoning in Russia: An Overview
Konstantine Brusin Sverdlovsk Regional Centre of Acute Poisonings, Ekaterinburg, Russia
Outcomes of 224 cases of 70% acetic acid poisonings treated in poison centre were analyzed. Severity of poisoning was minor in 31 cases, moderate in 81 and severe in 112. Fifty-nine patients died (26.3%). Esophageal or gastric strictures developed in 19 cases during the first month. Kidney failure that demanded hemodialysis developed with 45 patients, 25 of them died. Bleeding during the second and the third weeks developed with 42 patients, 28 of them died. Prednisolone was prescribed to 193 patients, but in 82 cases the course of treatment lasted from 1 to 3 days; 14 patients died in the first 3 days, 10 patients (14.7%) died later. Bleeding developed in eight cases and strictures took place in seven cases (12.1% of survival patients). In the other 111 cases, 30 patients died (27%). Bleeding developed in 30 cases and strictures took place in 11 cases (13.6% of survival patients). Five of 31 patients who were not treated with prednisolone died (16.1%), four patients developed bleeding and one of them developed stricture. Long-term prednisolone treatment was associated with higher bleeding and mortality rates; however, the rate of strictures was almost the same as the 3-days course or refusal of prednisolone.
The Association Between Computed Tomography (CT) and Endoscopy in Acute Corrosive Ingestion
